Project description
Next-generation influenza vaccines
The strategic goals of the EU-funded INCENTIVE project are to advance knowledge of the underlying mechanisms of poor responsiveness to influenza vaccines (IVs) and to develop two next-generation universal IVs. This is a partnership between Indian, European and US groups that address the global health and economic challenge posed by influenza infections. The objectives include: performing comprehensive profiling of responders and non-responders to licensed IVs in infants, children, adults and elderly in phase IV trials in Europe and India to identify the mechanisms of vaccine responsiveness; advancing the development of two next-generation vaccines by providing a proof-of-concept for vaccine efficacy in non-human primates for an antigen presenting cell-targeted nucleic acid vaccine and developing a computationally-optimized vaccine up to phase II clinical trials and vaccine efficacy in a controlled human challenge; identifying predictive biomarkers of responsiveness to vaccination for new diagnostics; implementing technology transfer; and performing a health systems and investment analysis.
Objective
The highly integrated INCENTIVE consortium represents true partnership between Indian and European/US groups that addresses the global health and economic challenge posed by influenza infections, to reduce the worldwide burden resulting from outbreaks. INCENTIVE’s strategic goals are to provide seminal knowledge on the underlying mechanisms of poor responsiveness to influenza vaccines in vulnerable individuals and advance the development of two next generation universal influenza vaccines. This is achieved by pursing the following specific objectives: 1) address the current knowledge gap by performing comprehensive immunome profiling of responders and non-responders to licensed influenza vaccines in infants, children, adults and elderly in parallel phase IV trials in Europe and India to identify the underlying mechanisms of vaccine responsiveness in different vulnerable populations and ethnical groups; 2) advance the development of two next generation universal vaccines, including an antigen presenting cell-targeted nucleic acid vaccine up to proof-of-concept for vaccine efficacy in non-human primates, and a computationally-derived second generation COBRA (Computationally-Optimized Broadly-Reactive Antigens) vaccine up to clinical development, comprising a phase I trial in Europe, a phase II trial in India and efficacy studies using an influenza controlled human challenge model; 3) identify predictive biomarkers of responsiveness to vaccination to develop new diagnostics; 4) implement comprehensive technology transfer and harmonization activities for immunological analysis and data integration; and 5) perform a health systems and investment analysis, and discrete choice experiments to assess the suitability of the developed technologies for low- and middle-income countries and to identify potential downstream constraints that might affect uptake by health care systems.
Fields of science
- natural sciencesbiological scienceszoologymammalogyprimatology
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
38124 Braunschweig
Germany
See on map
Participants (20)
110017 New Delhi
See on map
121001 Faridabad
See on map
1050 Bruxelles / Brussel
See on map
5020 Bergen
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
5021 Bergen
See on map
0313 Oslo
See on map
2000 Antwerpen
See on map
2333 ZA Leiden
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
2333 CL Leiden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75724 Paris
See on map
38302 Wolfenbuttel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08036 Barcelona
See on map
69007 Lyon
See on map
30602-7411 Athens
See on map
1901 XX Castricum
See on map
1003 Lausanne
See on map
19808 Wilmington New Castle
See on map
600036 Chennai
See on map
400012 Mumbai
See on map
110067 New Delhi
See on map